What is glutathione's most important effect?

Glutathione is the body's master antioxidant. It neutralizes reactive oxygen species, keeps vitamins C and E in their active form, and is a key player in liver detoxification. These roles in the body are very well established; the open question is only how much a supplement changes them.

Does oral glutathione actually work?

Partly, and slowly. As a tripeptide it is largely broken down in the gut. One controlled six-month trial (Richie 2015) found a rise in glutathione stores; a shorter four-week study (Allen 2011) found no reliable effect. So an effect via the oral route is possible, but slow, dose-dependent, and not yet clearly established in clinical benefit.

Does glutathione lighten skin?

The evidence is weak. Small studies report a slight, measurable lightening with oral intake over weeks by shifting melanin toward lighter pheomelanin. Reviews, however, rate the overall evidence as short-term and methodologically limited. The effect, where present, is mild and fades after stopping, and no regulator has approved glutathione for lightening.

Is intravenous glutathione safe?

This is the route with the greatest concerns. High-dose, unregulated IV infusions for skin lightening have been explicitly criticized by regulators, given reports of serious adverse effects and the absence of convincing controlled efficacy evidence. This is a characterization of the literature, not a dosing recommendation.

Is NAC better than glutathione?

Mechanistically that is a reasonable argument. Cysteine is the limiting precursor of the body's own glutathione synthesis, and N-acetylcysteine delivers cysteine more reliably than intact glutathione is absorbed. Whether that yields a visible cosmetic benefit in healthy people is unsettled, but as a lever on glutathione stores the precursor is the more plausible route.

Compound profile· Compounds

Glutathione, the body's antioxidant tripeptide and its limits

By The PepVise Editorial Team · Reviewed July 8, 2026 · 12 min read

Evidence Ledger

Glutathione: The Peptide Antioxidant, Assessed

Overall tier

State of the published literature as of July 2026. Sourced from PubMed, ClinicalTrials.gov, and FDA documents.

Preclinical: Animal / in vitro studies
Human pilot: Single-arm or small open-label
Phase trial: Phase 2 / 3 randomized
FDA status: Approved human indication

Notable

Glutathione's role as an endogenous antioxidant is not in question. Supplement evidence is thinner: oral absorption is limited and results mixed (Richie 2015 positive over months, Allen 2011 null over weeks), skin-lightening data is weak and short-term (Sonthalia 2018 review), and no regulator has approved glutathione for skin lightening. High-dose IV use carries documented safety concerns.

Glutathione is the body's master antioxidant, a tripeptide made in every cell. What it actually does, why oral absorption is the central problem, and what the studies show for skin, oxidative stress and safety, characterized against the evidence.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.

The PepVise Editorial Teamfrom the house style guide

Methodology

How we read the literature

Evidence tier: We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage: Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status: We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain: Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.

Frequently asked

The questions readers actually bring us.

What is glutathione's most important effect?: Glutathione is the body's master antioxidant. It neutralizes reactive oxygen species, keeps vitamins C and E in their active form, and is a key player in liver detoxification. These roles in the body are very well established; the open question is only how much a supplement changes them.
Does oral glutathione actually work?: Partly, and slowly. As a tripeptide it is largely broken down in the gut. One controlled six-month trial (Richie 2015) found a rise in glutathione stores; a shorter four-week study (Allen 2011) found no reliable effect. So an effect via the oral route is possible, but slow, dose-dependent, and not yet clearly established in clinical benefit.
Does glutathione lighten skin?: The evidence is weak. Small studies report a slight, measurable lightening with oral intake over weeks by shifting melanin toward lighter pheomelanin. Reviews, however, rate the overall evidence as short-term and methodologically limited. The effect, where present, is mild and fades after stopping, and no regulator has approved glutathione for lightening.
Is intravenous glutathione safe?: This is the route with the greatest concerns. High-dose, unregulated IV infusions for skin lightening have been explicitly criticized by regulators, given reports of serious adverse effects and the absence of convincing controlled efficacy evidence. This is a characterization of the literature, not a dosing recommendation.
Is NAC better than glutathione?: Mechanistically that is a reasonable argument. Cysteine is the limiting precursor of the body's own glutathione synthesis, and N-acetylcysteine delivers cysteine more reliably than intact glutathione is absorbed. Whether that yields a visible cosmetic benefit in healthy people is unsettled, but as a lever on glutathione stores the precursor is the more plausible route.

What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The sources

References cited on this page.

PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min read

Compounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min read

Compounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.